190 related articles for article (PubMed ID: 26423594)
1. Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients.
Bellini V; Bianchi L; Pelliccia S; Lisi P
J Cutan Pathol; 2016 Mar; 43(3):211-8. PubMed ID: 26423594
[TBL] [Abstract][Full Text] [Related]
2. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
3. Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series.
Kuo KY; Kwong B; Rahman Z
J Cosmet Laser Ther; 2017 Oct; 19(5):300-302. PubMed ID: 28463045
[TBL] [Abstract][Full Text] [Related]
4. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph K; Pongcharoen P; Vachiramon V
Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
[TBL] [Abstract][Full Text] [Related]
6. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
7. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin.
Akoglu G; Yavuz SO; Metin A
Indian J Pharmacol; 2016; 48(3):324-6. PubMed ID: 27298507
[TBL] [Abstract][Full Text] [Related]
10. [Skin signs associated with epidermal growth factor inhibitors].
Hannoud S; Rixe O; Bloch J; Le Pelletier F; Lebrun-Vignes B; Doarika A; Khayat D; Chosidow O
Ann Dermatol Venereol; 2006 Mar; 133(3):239-42. PubMed ID: 16800173
[TBL] [Abstract][Full Text] [Related]
11. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
[TBL] [Abstract][Full Text] [Related]
12. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
13. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
[TBL] [Abstract][Full Text] [Related]
14. Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.
Chmielinska JJ; Kramer JH; Mak IT; Spurney CF; Weglicki WB
Mol Cell Biochem; 2020 Feb; 465(1-2):175-185. PubMed ID: 31853800
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
Nikolaou V; Strimpakos AS; Stratigos A; Katsambas A; Antoniou C; Syrigos KN
Dermatology; 2012; 224(4):315-9. PubMed ID: 22699716
[TBL] [Abstract][Full Text] [Related]
16. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
[TBL] [Abstract][Full Text] [Related]
17. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
19. A case of successfully treated recalcitrant EGFR inhibitor-induced acneiform eruption following non-ablative fractional laser.
Choi JW; Kim TI; Jeong KH; Shin MK
Dermatol Ther; 2016 Jul; 29(4):252-4. PubMed ID: 27146102
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]